Header Logo

Connection

Joan Walker to Double-Blind Method

This is a "connection" page, showing publications Joan Walker has written about Double-Blind Method.
Connection Strength

0.283
  1. 5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial. J Invest Dermatol. 2017 06; 137(6):1367-1370.
    View in: PubMed
    Score: 0.127
  2. Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2025 Aug 21; 393(8):774-785.
    View in: PubMed
    Score: 0.055
  3. Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2021 01; 132(1):150-159.
    View in: PubMed
    Score: 0.041
  4. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 11; 151(2):257-263.
    View in: PubMed
    Score: 0.035
  5. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20; 32(12):1210-7.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.